DANONE S/ADR - DANOY STOCK NEWS

On June 20, 2024, Danone unveiled the next phase of its Renew strategy focused on advancing health and nutrition. The company shared its mid-term strategy for 2025-2028 during a Capital Market Event, emphasizing science, innovation, operational discipline, and proactive portfolio management. Danone plans to pivot its approach to protein and gut health, expand business models in away-from-home and medical nutrition, and grow geographically. CEO Antoine de Saint-Affrique highlighted the company's transformation and commitment to delivering 3-5% net sales growth and higher recurring operating income. The event is available on Danone's website.

Danone, DMC Biotechnologies, Michelin, and Crédit Agricole Centre France have partnered to establish a state-of-the-art biotechnology platform in Clermont-Ferrand. The Biotech Open Platform, with an initial investment exceeding 16 million euros, aims to advance precision fermentation, a key biotechnological process for producing bio-based materials and ingredients. Supported by various public and private entities, this initiative seeks to scale up precision fermentation technologies from laboratory to industrial levels. By 2025, the project plans to install a demo-scale production line to enhance the development of bio-sourced materials, addressing industry needs for sustainable and innovative alternatives to fossil-based resources.

Danone disclosed the total number of shares and voting rights as of May 31, 2024. The company, listed under the stock symbol DANOY, registered a total of 679,260,800 shares. The total theoretical voting rights stood at 700,820,680, while the total exercisable voting rights were 664,921,936. These figures comply with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Financial Markets Authority (AMF). The publication aims to ensure transparency in shareholder voting dynamics, differentiating between 'gross' and 'net' voting rights as recommended by the AMF.

On May 17, 2024, Danone announced it has completed the sale of its Essential Dairy and Plant-based (EDP) business in Russia to Vamin R This follows the initial announcement on March 22, 2024, confirming the receipt of required Russian regulatory approvals for the transaction. The divestment is part of Danone's broader strategic initiative to streamline its portfolio and focus on key growth areas.

Danone has reported the total number of voting rights and shares as of April 30, 2024. The company, listed in Paris, has a capital of €169,443,282 and is registered under the number 552 032 534. As per the report, Danone has 677,773,128 shares. The total number of theoretical voting rights is 698,764,592, while the total number of exercisable voting rights is 662,863,346. The theoretical voting rights include all shares, even those with suspended voting rights, while the exercisable voting rights exclude such shares, adhering to AMF guidelines.

Danone has acquired Functional Formularies, a whole foods tube feeding business in the US, to strengthen its Medical Nutrition portfolio and expand its enteral tube feeding ranges as part of the Renew Danone strategy. This acquisition adds a differentiated product portfolio to support the nutritional needs of tube-fed families and patients.

Danone successfully issued a €700 million bond with a 6-year maturity and a 3.481% coupon. The bond issuance enhances funding flexibility and extends debt maturity, settling on May 3, 2024, and listing on Euronext Paris. The diversified investor base reflects high confidence in Danone's business model and credit profile.